[go: up one dir, main page]

TN2009000147A1 - Crystal modifications -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-d ione - Google Patents

Crystal modifications -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-d ione

Info

Publication number
TN2009000147A1
TN2009000147A1 TNP2009000147A TN2009000147A TN2009000147A1 TN 2009000147 A1 TN2009000147 A1 TN 2009000147A1 TN P2009000147 A TNP2009000147 A TN P2009000147A TN 2009000147 A TN2009000147 A TN 2009000147A TN 2009000147 A1 TN2009000147 A1 TN 2009000147A1
Authority
TN
Tunisia
Prior art keywords
quinazolin
piperazin
indol
pyrrole
methyl
Prior art date
Application number
TNP2009000147A
Other languages
English (en)
Inventor
Piotr Karpinski
Stephanie Monnier
Elias Ndzie
Dimitris Papoutsakis
Paul Allen Sutton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000147(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000147A1 publication Critical patent/TN2009000147A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2009000147A 2006-10-20 2009-04-17 Crystal modifications -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-d ione TN2009000147A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85338406P 2006-10-20 2006-10-20
PCT/US2007/022241 WO2008051440A1 (fr) 2006-10-20 2007-10-18 Modifications cristallines

Publications (1)

Publication Number Publication Date
TN2009000147A1 true TN2009000147A1 (en) 2010-10-18

Family

ID=38921707

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000147A TN2009000147A1 (en) 2006-10-20 2009-04-17 Crystal modifications -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-d ione

Country Status (23)

Country Link
US (1) US8865897B2 (fr)
EP (1) EP2102195A1 (fr)
JP (1) JP5302199B2 (fr)
KR (1) KR20090073231A (fr)
CN (2) CN103265533A (fr)
AR (1) AR063491A1 (fr)
AU (1) AU2007309558B2 (fr)
BR (1) BRPI0717461A2 (fr)
CA (1) CA2666965A1 (fr)
CL (1) CL2007003006A1 (fr)
EC (1) ECSP099344A (fr)
IL (1) IL197962A (fr)
MA (1) MA30886B1 (fr)
MX (1) MX2009004048A (fr)
MY (1) MY158026A (fr)
NO (1) NO20091970L (fr)
NZ (1) NZ576241A (fr)
PE (1) PE20081133A1 (fr)
RU (1) RU2481341C2 (fr)
TN (1) TN2009000147A1 (fr)
TW (1) TWI399374B (fr)
WO (1) WO2008051440A1 (fr)
ZA (1) ZA200902048B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100093749A1 (en) * 2007-03-09 2010-04-15 Novartis Ag Compounds
US9005409B2 (en) 2011-04-14 2015-04-14 Tel Nexx, Inc. Electro chemical deposition and replenishment apparatus
US9017528B2 (en) 2011-04-14 2015-04-28 Tel Nexx, Inc. Electro chemical deposition and replenishment apparatus
US9303329B2 (en) 2013-11-11 2016-04-05 Tel Nexx, Inc. Electrochemical deposition apparatus with remote catholyte fluid management

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60140201D1 (en) * 2000-11-07 2009-11-26 Novartis Ag Indolylmaleimidderivative als proteinkinase-c-inhibitoren
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
AU2008266515B2 (en) 2007-06-18 2014-05-01 Sanofi Pyrrole derivatives as P2Y12 antagonists

Also Published As

Publication number Publication date
CN103265533A (zh) 2013-08-28
BRPI0717461A2 (pt) 2013-10-08
US20100041884A1 (en) 2010-02-18
CL2007003006A1 (es) 2008-05-23
CN101522664B (zh) 2013-06-12
KR20090073231A (ko) 2009-07-02
US8865897B2 (en) 2014-10-21
MY158026A (en) 2016-08-30
ECSP099344A (es) 2009-06-30
EP2102195A1 (fr) 2009-09-23
RU2009118816A (ru) 2010-11-27
AR063491A1 (es) 2009-01-28
TWI399374B (zh) 2013-06-21
WO2008051440A1 (fr) 2008-05-02
NZ576241A (en) 2012-05-25
IL197962A0 (en) 2009-12-24
AU2007309558B2 (en) 2012-05-24
JP2010506927A (ja) 2010-03-04
NO20091970L (no) 2009-05-20
ZA200902048B (en) 2010-01-27
AU2007309558A1 (en) 2008-05-02
MA30886B1 (fr) 2009-11-02
TW200829572A (en) 2008-07-16
CA2666965A1 (fr) 2008-05-02
JP5302199B2 (ja) 2013-10-02
IL197962A (en) 2013-08-29
RU2481341C2 (ru) 2013-05-10
CN101522664A (zh) 2009-09-02
PE20081133A1 (es) 2008-09-16
MX2009004048A (es) 2009-04-27

Similar Documents

Publication Publication Date Title
WO2010002655A3 (fr) Composés et compositions en tant qu’inhibiteurs de kinase
MX2010002336A (es) Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.
TW200626068A (en) Active compounds for seed treatment
UA101346C2 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы как гербициды
MY146989A (en) Kinase inhibitors
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
TW200618800A (en) Heterocyclic compounds
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
SG170772A1 (en) Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
UA101057C2 (en) Pyrimidine derivatives as kinase inhibitors
UA104731C2 (ru) Ингибиторы р38 мар-киназ
AU2011276193A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
TW200621721A (en) Methods of preparing indazole compounds
WO2008053334A3 (fr) Procédé amélioré de préparation de rosuvastatine calcique
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
TW200738651A (en) Cyclohexyl sulfonamide derivatives
MX2011012629A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
MX2011012632A (es) Inhibidores de actividad de cinasa tipo pirimidina.
EA201100696A1 (ru) 1-(арилсульфонил)-4-(пиперазин-1-ил)-1h-бензимидазолы в качестве лигандов 5-гидрокситриптамина-6
MX2011006560A (es) Derivados heterociclicos fucionados con oxadiazola utiles para el tratamiento de esclerosis multiple.
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
MX2009004947A (es) Arilsulfonil-pirrolidinas como inhibidores 5-hidroxitriptaminas6 (5-ht6).